EphA2-targeted CAR-DCs

EphA2-targeted CAR-DCs are **dendritic cells genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen EphA2**. EphA2 is highly expressed in multiple cancer types, including glioblastoma and non–small cell lung cancer. The CAR-DC approach involves modifying dendritic cells to display anti-EphA2 CARs, aiming to enhance antigen presentation and stimulate potent anti-tumor T-cell responses. Several clinical trials are evaluating EphA2-targeted CAR-DCs either as monotherapy or in combination with other immunotherapies (such as CAR-T cells or immune checkpoint inhibitors), in various cancer indications including advanced/metastatic solid tumors. Early clinical data suggest a favorable safety profile and immune system activation. Mechanistically, this therapy bridges **cell therapy**, **dendritic cell therapy**, and **CAR-mediated targeted immunotherapy**[5][6][7][9].